Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
News
All
Press Releases
News Articles
/?php if (has_post_thumbnail()) { ?> /?php } ?>
News Articles
September 01, 2022
A new gene therapy based on antibody cells is about to be tested in humans
Genetically-engineered B cells, the cells that make our bodies' antibodies, will be harnessed to treat a rare disease.
Related
Press Releases
PR Newswire | January 26, 2026
Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
Read More
/?php if ( is_home()) { ?> /?php } ?>
News Articles
Genetic Engineering & Biotechnology News | January 13, 2026
Fast-Tracked CGT Platform Eliminates Patient Preconditioning
Immusoft’s MPS 1 CGT therapeutic hurdles traditional barriers, eliminating patient preconditioning and enabling redosing
Read More
/?php if ( is_home()) { ?> /?php } ?>